首页 >> 研究进展
A clinical trial on anti-HBV-DC vaccine combined with thymosin-α1 in the inactive HBsAg carriers
发布时间: 2013-06-20    人气指数:1016

APASL 2013---The 23th Conference of the Asian Pacific Association for the Study of the Liver

Poster Presentation(Abstract NO 1131)

Hepatology International. 2013, 7(Suppl 1):s227.


Bang-Fu Wu1,2, Jiang-Ying Yang2, Ya-Lin Zhang3, Yong Liu1, Hui-Hua Zhou3, Xuan-Qin Wang1, Fang-Qin Li1, Chun-Qiong Hou3, Xue-Song Li1, Xiang-Hua Huang1, Zheng-Sheng Xiao1, Ming Yang1, Fu-Xin Lin3, Yan-Ping Fu3, Shuo Zheng3, Wei Chen3, Yun Zhou2, Jun Yang2, Xin-He Wan1, Hui Huang1


1.Gastroenterology and Hepatology Center, Southern Medical University Renkang Hospital, Houjie Dongxi Road, No.88, Dongguan 523952, China

2 Guangzhou Pubang Bio-Immunological Tech Research Institute, Kezhu Road, No.232-2, Room 205, Guangzhou Science City, Luogang District, Guangzhou 510663, China

3 Gastroenterology and Hepatology Center, Tongji Medical College Affiliated Dongguan Hospital, Huazhong University of Science and Technology, Liaobu Southwest Road, No.171-175, Dongguan 523416, China


Background/Aims: To observe the clinical efficacy of anti-HBV-DC vaccine, the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg, in combination with thymosin-α1, in the inactive HBsAg carriers. 

Methods:24 inactive HBsAg carriers were recruited in the trial including 15 males and 9 females aged 18-57 years. PBMCs obtained from 50ml of heparinized peripheral blood through density gradient centrifuge and adherence method were proliferated under the induction by GM-CSF and IL-4, and sensitized with the stock of hepatitis B vaccine containing 30µg HBsAg on day 5 and with hepatitis B vaccine commercially available containing 20µg HBsAg on day 6. anti-HBV-DC vaccine was harvested on day 7 and injected, half hypodermically and half intravenously, to the patient once every two weeks for 12 practices applications totally. Thymosin-α1 1.6mg was injected hypodermically twice a week. Quantitative HBVM(TRFIA) and HBVDNA and hepatic functions were evaluated at week 0, 4, 12, and 24.
Results: Mean of HBsAg decreased gradually along the time from week 4, 12 to 24, with significant difference compared with the values prior to treatment. At week 4, 12 and 24, HBsAg negative conversion rate were 12.50%(3/24), 25.00%(6/24) and 37.50%(9/24) respectively. 

The rate of adverse effect was 2.78% observed in reinfusion of anti-HBV-DC vaccine.

Conclusions: anti-HBV-DC vaccine in combination with thymosin-α1 can be considered as a safe approach with high efficacy for inactive HBsAg carriers, which can decrease rapidly the HBsAg, and may eliminate the HBsAg for partial inactive HBsAg carriers.

Author Keywords: Dendritic cells (DC); Hepatitis B virus (HBV); Inactive HBsAg carriers; Vaccine